HCA is procuring a vendor for PDL development and once finalized, more information will be posted here
Pharmacy and Therapeutics (P&T) and Drug Utilization Review (DUR) Committee
In 2026 New Mexico Health Care Authority will implement a statewide Preferred Drug List (PDL) designed to streamline medication access for Medicaid members and simplify prescribing practices. The New Mexico Health Care Authority is currently seeking qualified healthcare professionals to serve on the combined Pharmacy and Therapeutics (P&T) and Drug Utilization Review (DUR) Committee. We invite interested providers with relevant expertise to apply for membership. The P&T/DUR Committee plays a critical role in ensuring safe, effective, and evidence-based use of medications within the state’s healthcare programs. Members review clinical evidence, provide recommendations to the Medicaid CMO, and develop guidance on pharmaceutical policies that impact patient care statewide.
We are seeking applicants who:
- Are licensed healthcare providers in good standing (e.g., physicians, pharmacists, advanced practice providers)
- Have experience in pharmacotherapy, clinical practice, or medication management
- Can commit to attending scheduled meetings and participating in evidence review and committee discussions (mandatory 4-hour meeting per quarter, 2-4 hours of associated work)
- Are able to serve 3-year term without conflicts of interest
To apply, please submit the following:
- A current CV or résumé
- A brief statement of interest describing relevant experience and qualifications
Please send all application materials to Cynthia.Gustafson@hca.nm.gov by 12/12/2025. Decision to be made by January 2026.
We appreciate your commitment to improving patient care and thank you in advance for your interest in serving on this important committee.
Return to Pharmacy Main Page
